Commerce Bank bought a new stake in Stryker Corporation (NYSE:SYK - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 120,562 shares of the medical technology company's stock, valued at approximately $37,958,000.
A number of other large investors have also recently made changes to their positions in SYK. Norges Bank purchased a new stake in Stryker in the 4th quarter worth about $1,822,272,000. Auto Owners Insurance Co boosted its position in shares of Stryker by 35,047.0% during the fourth quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company's stock valued at $1,024,444,000 after buying an additional 2,906,448 shares during the period. Flossbach Von Storch SE bought a new position in shares of Stryker during the second quarter valued at approximately $464,506,000. Wellington Management Group LLP grew its stake in shares of Stryker by 22.6% during the fourth quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company's stock valued at $2,282,192,000 after buying an additional 1,198,665 shares during the last quarter. Finally, Corient Private Wealth LLC raised its holdings in shares of Stryker by 104.4% in the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company's stock worth $887,525,000 after buying an additional 1,146,998 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
SYK has been the subject of a number of recent analyst reports. Wolfe Research cut Stryker from an "outperform" rating to a "peer perform" rating in a report on Thursday, August 13th. Robert W. Baird set a $385.00 target price on Stryker in a research note on Friday, May 1st. Royal Bank Of Canada decreased their target price on Stryker from $435.00 to $420.00 and set an "outperform" rating for the company in a research report on Friday, July 31st. Truist Financial boosted their target price on shares of Stryker from $330.00 to $340.00 and gave the company a "hold" rating in a research note on Friday, July 31st. Finally, Citigroup restated a "buy" rating on shares of Stryker in a report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $386.28.
Read Our Latest Analysis on SYK
Key Headlines Impacting Stryker
Here are the key news stories impacting Stryker this week:
- Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here's Why You Should Hold Stryker Stock in Your Portfolio for Now
- Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
- Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
- Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
- Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis
Stryker Stock Up 0.7%
Shares of NYSE SYK opened at $329.86 on Friday. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $396.86. The firm has a market capitalization of $126.52 billion, a price-to-earnings ratio of 34.18, a PEG ratio of 2.10 and a beta of 0.76. The stock has a 50 day moving average price of $326.99 and a 200 day moving average price of $332.64. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16.
Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker's quarterly revenue was up 9.4% on a year-over-year basis. During the same period last year, the business posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts expect that Stryker Corporation will post 15.02 earnings per share for the current year.
Stryker Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker's dividend payout ratio (DPR) is currently 36.48%.
Insider Activity at Stryker
In related news, insider Debra King sold 826 shares of Stryker stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the sale, the insider directly owned 6,210 shares in the company, valued at $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of the company's stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares of the company's stock, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 665,370 shares of company stock worth $216,238,501 over the last three months. 4.60% of the stock is owned by corporate insiders.
About Stryker
(
Free Report)
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
